title: Salvage immuno-chemotherapy with a combination of rituximab, high-dose cytarabine, mitoxantrone and dexamethasone for patients with primary CNS lymphoma: a preliminary study.
authors.forename: Ryuya
authors.initials: R
authors.lastname: Yamanaka
authors.forename: Junpei
authors.initials: J
authors.lastname: Homma
authors.forename: Masakazu
authors.initials: M
authors.lastname: Sano
authors.forename: Naoto
authors.initials: N
authors.lastname: Tsuchiya
authors.forename: Naoki
authors.initials: N
authors.lastname: Yajima
authors.forename: Hideaki
authors.initials: H
authors.lastname: Takahashi
authors.forename: Yoshikatsu
authors.initials: Y
authors.lastname: Shinbo
authors.forename: Akira
authors.initials: A
authors.lastname: Hasegawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Saitoh
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Tanaka
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy / Q000401:mortality; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000401:mortality; D003561:Cytarabine / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000627:therapeutic use; D000069283:Rituximab; D016879:Salvage Therapy / Q000379:methods*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D003561:Cytarabine; D000069283:Rituximab; D003907:Dexamethasone; D008942:Mitoxantrone